In the article by Ponikowski et al. 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. Eur Heart J. 2016;37:2129-2200, the following sentence, which appeared in the ahead of print version, has been eliminated: “In the SIGNIFY trial in patients with activity-limiting angina without HF, ivabradine increased the risk of death from cardiovascular causes or non-fatal myocardial infarction and therefore is not recommended in this setting.”
The Spanish translation of the guideline, published in Rev Esp Cardiol. 2016;69:1167.e1-e85, was based on the first ahead of print version. After the publication of the correct print version in European Heart Journal and communication of this discrepancy, the translation of this sentence was eliminated from the electronic version of the article on February 23, 2017.